Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL DosePro

Zogenix Inc.

, a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Mallinckrodt LLC, the pharmaceuticals business of Covidien

, today announced an exclusive co-promotion agreement for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System in the United States. Under terms of the agreement, Mallinckrodt's sales team will begin selling SUMAVEL DosePro to its customer base of prescribers. The initial term of the agreement will be through June 30, 2014, and can be extended by mutual agreement of the parties in additional six month increments. Zogenix will continue to record all product revenues and Mallinckrodt will be compensated in the form of a quarterly service fee that is calculated as a percentage of net sales over a baseline amount to their prescriber audience. SUMAVEL DosePro is the first and only needle-free delivery system for subcutaneous sumatriptan for the treatment of acute migraine and cluster headache. Clinical data has shown that SUMAVEL DosePro can provide migraine pain relief within 10 minutes for some patients (16% of patients versus 4% for placebo). The product was launched in January 2010 and sales have grown sequentially every quarter since launch, reaching over 129,000 total prescriptions at the end of the first quarter 2012.